New bill aims to allow research to catch up with US’s increasing cannabis consumption | US news
recently Bell presentedIf it passes, it will be allowed to search Hashish Despite his position in the first table, which some experts say policymakers can help in “literal” legislation in the future and may allow more clinical research about medical cannabis.
Actors Dina Titus and Ilhan Omar The EBDPA -based drug policy law (EBDPA) was presented last week, which radically relieves research restrictions on hemp and other tables.
Omar said in a statement that the law will allow research to kneel to continue the consumption of cannabis in the United States: “We need a drug policy to follow the science and reflect the reality on the ground in the states throughout the country.”
The first table materials, including cannabis, heroin and MDMA, are defined as “no acceptable medical use” and “high ability to abuse”. Medical cannabis supporters indicate that the first federal schedule in the first hemp is contradictory, given that patients all over the United States are already using cannabis for medical purposes.
The Biden Administration has prompted the re -classification of cannabis as the third table, which would change its legal status and make cannabis -based drugs eligible to obtain the approval of the Food and Drug Administration.
However, the renovation process has continued in the situation since Donald Trump entered the Oval Office.
Unlike the renovation, the EBDPA will be simple to age. There The current formIt cancels sections from the 1998 National Drug Policy Policy Policy Office that prevents federal funds from going to search for first table materials, which require ONDCP to oppose any attempts to legalize the first subjects.
However, there are questions about whether this bill has the ability to pass.
Catherine Neil Harris, a drug policy colleague at Rice University, says the bill is a “modest proposal” and “may be possible to obtain support for the two parties he needs.”
Cat Packer, Director of Narcotics Markets and Legal Organization in the Narcotics Policy Alliance, notes that the draft law “has the ability to attract support from the two parties as a modest but meaningful step forward” due to giving priority “evidence of ideology.”
Although the most comprehensive federal hemp may be in the distant future, “EBDPA should be considered a neutral step that enables politics to study what succeeds – and be better to formulate effective and enlightened legislation in the future,” added Baker.
On the other hand, Aaron Smith, CEO of the citizen Hashish The Industry Association does not feel hope, and because of “the severe partisan times in which we live, or obtaining this bill, or any legislation, frankly, is unlikely in the short term.”
Pacte hopes that political makers will see that the draft law is vital to the formation of a smart hemp policy.
“The federal government cannot learn beneficially from the experiences of the 24 states that led to the law of cannabis,” says Baker on the current situation.
There are currently no ways to measure the federal government a scientific impact on youth consumption and health results, detention and prison rates, who economically benefit from the legal hemp policies, in exchange for those who are excluded.
Bakr said that the current policy is not only old, but there is “the foundation of the institutional eyes that prevents the federal government from adapting to real conditions and designing effective and responsive policies.”
Ideally, Harris says that the law will lead to “an increase in strict research to report the practice of medical use”, noting that there are many questions when it comes to how hemp works as a medicine, about ideal doses, long -term effects of different consumption methods, and whether certain strains work better than some cases than others.
While Omar and Tios emphasized hashish when promoting the draft law, it will allow federal financing to search for research on the articles of the other first schedule as well.
“The drug policy must be rooted in the scientific fact” and that any step in this direction should be formulated. Harris repeated these feelings, noting that research on the materials of the other first table “affects the need”, given that “many materials in the first table-Psilocybin and MDMA in particular, seem to have therapeutic effects for some people who are difficult to treat.” Federal government -funded medical research on the effectiveness of these drugs can provide medicine in the United States.
Harris said: “If there is evidence that supports the approval of the Food and Drug Administration on drugs, the first schedule of therapeutic applications, then this law means that the National Drug Control Policy Office will not contradict reflex.”
If the draft law is passed, Harris is skeptical of the amount of federal financing that he will actually go to the first table, as the Trump administration, so far, seems to be opposed to funding federal research on a broader scale. “
However, she says: “This bill is an important and reasonable effort to improve the sensitivity of federal drug policies, but the current climate can inhibit its short -term effects.”
